The publication, based on data generated from a questionnaire with 150 industry representatives, explores the challenges and solutions facing cell and gene therapy (CGT) companies over the next few years.
The top six trends identified in the CRB survey were:
We got the inside track from Noel Maestre, director of SlateXpace, a CRB solution focused on suite-based manufacturing platforms for the Advanced Therapy Medicinal Products (ATMP) and Peter Walters, CRBs director of ATMP, on how the CGT landscape is likely to develop in the short-term.
In a recent report, the MITs Center for Biomedical Innovationprojected that around 500,000 patients will have been treated with 40-60 approved gene therapies by 2030.
Going from the current scenario whereby only a few gene therapies are approved to 60 launches in a decade would represent an extraordinary leap forward and would dramatically change how medicine is actually perceived, said Maestre.
But as regards CGT production today, especially autologous cell therapy (ACT) work, he said that while the science exists the technology - process equipment, facility design and automation platforms - is really still trying to catch up, endeavoring to address a sector that has exploded in the past five years, he commented.
Looking ahead at the CGT landscape over the next few years, he expects a significant amount of change. The science is evolving we see the industry moving away from old cell lines to new cell lines or moving away from viral vectors altogether and using cleavage enzymes as a gene editing tool.
A new host cell line stable producer lines is gaining momentum, he said.
We are seeing the industry moving towards suspension cell culture from less than optimal cell lines, and then further going into producer cell lines.
A full 65% of respondents to the CRB poll said they are developing or intend to develop this type of vector host cell, drawn by the potential for a less expensive, more scalable process.
CRB: Our survey findings provide a data-driven snapshot of an industry whose intellectual capital and cutting-edge science is too often betrayed by outdated technology and applications ill-suited for commercial scale at a time when demand for urgent therapies is rising.
Once the industry gets to the point where producer cell lines are more like a name brand, easier to pull off the shelf and use, it will be a much more cost-effective way to produce viral vectors.
But we are right on the cusp - a lot of companies are recognizing the opportunity and are investing the time and money into producing these. And we also see a lot of contract development and manufacturing organizations (CDMOs) producing their own cell lines in house and using those as a lure to [attract the clinical material work] of their clients, said Walters.
According to Maestre, and the CRB survey data backs him up, the product pipelines of companies operating in the CGT space are going to get more complex, for the next five years at least.
More than half of those polled indicated they expect to adopt a multimodal solution within the next two years, with flexibility, scalability, operational efficiency, and speed to market as the top drivers.
Every company is going to be dealing with this dilemma of whether they build dedicated spaces for each of their different modalities, or whether they build highly flexible facilities that can allow them to accommodate whatever is coming next, said Maestre.
He also sees a lot more companies wanting to integrate their supply chain, bringing a lot of manufacturing in-house whereas before they would have been reliant on a whole set of different CDMOs and manufacturers.
Project delivery is also where change is occurring.
We are seeing the industry really moving away from the way projects were executed in the past into a much more integrated model; they are looking for turnkey facility delivery and they want turnaround to be faster. COVID-19 has only accentuated that, with project timelines compressed by 30-40%, and I dont think that it is ever going back to the way it was I think that is going to become the standard, commented Maestre.
And another major trend over the next few years will be around the cost of therapies. As they become more commonplace and there are more and more CGT licensed products, the costs will come down.
Projecting forward, Walters sees an eventual shift away from autologous to allogeneic cell therapy.
As the technology continues to develop and the science continues to improve and new and better ways are found to use and leverage cells, we will see companies moving to a scalable allogeneic model, getting away from having to do that point-of-care, personalized tracking and more towards a classic manufacturing model that allows them to produce cells in advance in a way that they can be scaled up.
The idea, evidently, is to process cells for not one but dozens of patients at a time.
We see the industry moving towards donated cells for allogeneic therapy and we are also seeing the beginnings of a shift to using stem cells that can be genetically modified and scaled up and differentiated to become T-Cells or NK cells. I dont think industry has settled on a course yet but there are a lot of companies trying to find that pathway, trying to find the edge to move their manufacturing platform that way, remarked Walters.
Right now, though, all facets of CGT manufacturing are under pressure from COVID-19 vaccine production, they said.
There is significant shortage of cleanroom manufacturing space to manufacture and develop the almost 1,200 CGT products in clinical trials currently.
What we are seeing is that CDMOs have so much demand - they have 12-18 months of backlog in terms of contracts for product development so they are building [new facilities] very rapidly.
As owner operator companies are stuck with that delay in getting their products into development, they are also developing a significant amount of manufacturing space on their own. But while both branches are building as fast as they can, it still isnt enough.
We are constantly hearing from our clients that they are concerned about their supply chains and being able to secure their material. Right now, a lot of companies are moving towards a combination of using CDMOs and manufacturing in-house, said Maestre.
CRB is a provider of engineering, architecture, construction and consulting solutions to the global life sciences and advanced technology industries, with over 1,300 employees.
- The #1 Best Tea for Fat Loss, According to Nutritionists | Eat This Not That - Eat This, Not That - January 19th, 2021
- Adipose Derived Stem Cell Therapy Market 2018: Production, Sales, Supply, Demand, Analysis and Forecast To 2026 | BioRestorative Therapies, Inc.,... - January 19th, 2021
- Papaya leaf juice: Health benefits, how to make and the right way to consume - Times of India - January 19th, 2021
- Can We Enjoy Meat and Seafood and Save the Planet? - EcoWatch - January 16th, 2021
- COVID self-care tips for skin, hair and overall wellness - Los Angeles Times - January 16th, 2021
- AltuCell Therapeutics Announces Proof-of-Concept in Lead Programs in Type 1 Diabetes in Human Subjects; Phase 1 Pilot in Humans Has IND Approval &... - January 16th, 2021
- Co-founder Thomas Smeenk on the benefits of Hemostemix autologous stem cell therapy - InvestorIntel - January 14th, 2021
- Seattle researchers find clues for treatments that could eliminate HIV in infected patients - GeekWire - January 14th, 2021
- Warm Up with Homemade Broths and Stocks - The Source Weekly - January 14th, 2021
- Orchard Therapeutics Announces 2021 Corporate Priorities Supporting the Build-out of its Commercial Business in Hematopoietic Stem Cell (HSC) Gene... - January 14th, 2021
- Canine Stem Cell Therapy Market: Insights & Overview with Potential Impact Of COVID-19, Key Trends and Business Opportunity - Murphy's Hockey Law - January 14th, 2021
- Improve freezing of stem cells and tissues | Gazette - Inspired Traveler - January 14th, 2021
- Switching to the Mediterranean Diet Can Reduce the Risk of Having a Second Heart Attack - Olive Oil Times - January 14th, 2021
- Celularity and GX Acquisition announce merger agreement to create publicly listed leader in allogeneic cellular therapy - Pharmaceutical Business... - January 14th, 2021
- Can Retinol and Niacinamide Be Used Together? Here's What the Experts Had to Say - POPSUGAR - January 14th, 2021
- Top 10 ALS Stories of 2020 - ALS News Today - January 10th, 2021
- Comparison of the efficiency, safety, and survival outcomes in two stem cell mobilization regimens with cyclophosphamide plus G-CSF or G-CSF alone in... - January 10th, 2021
- 10 incredible benefits of Giloy - Times of India - January 10th, 2021
- Worldwide Organ and Tissue Transplantation and Alternatives Industry to 2024 - Featuring Mylan, Novartis & Pfizer Among Others -... - January 10th, 2021
- Which muscle groups to work out together, from beginner to advanced - Medical News Today - January 10th, 2021
- 20 Inspiring Vegan TED Talks to Watch Right Now - VegNews - January 10th, 2021
- How to stop the next pandemic | WIRED UK - Wired.co.uk - January 6th, 2021
- Forge Biologics Announces FDA Clearance of Investigational New Drug Application for Phase 1/2 Clinical Trial (RESKUE) of FBX-101 Gene Therapy for... - January 4th, 2021
- Healing from the inside out - Around DB and Life on Lantau - January 4th, 2021
- Stem Cells Types, Technologies And Therapeutics Market Potential Growth, Size, Share, Trends, Demand and Analysis of Top Key-Players and Research... - January 3rd, 2021
- What is Kohlrabi, its benefits and how to add it to your diet? - Times of India - January 3rd, 2021
- Ozone in the air is bad for birds - Massive Science - January 3rd, 2021
- How good are the COVID-19 vaccines? - Massive Science - January 3rd, 2021
- Do we have to age? - The Guardian - January 3rd, 2021
- Neural Stem Cells Industry Market Revenue, Key Players, Supply-Demand, Investment Feasibility and Forecast By 2025 key Players | , Axol Bioscience,... - December 28th, 2020
- Exosomes act as messengers and decoys to save healthy cells from viral infection - Massive Science - December 28th, 2020
- For progressives, listen to science is subjective - Boston Herald - December 28th, 2020
- Webinar on benefits of 3D cell culture techniques - SelectScience - December 23rd, 2020
- Webinar on benefits of 3D cell culture techniques - SelectScience - December 23rd, 2020
- Scientists have restored youth to aging eyes in mice - Massive Science - December 23rd, 2020
- Is Singapores approval of lab-grown meat a win for the climate? - The World - December 23rd, 2020
- The 11 most mind-blowing, awe-inspiring health discoveries and innovations of 2020 - Business Insider - Business Insider - December 23rd, 2020
- Cultured Protein: A Guide To Every Cell-Based Meat Startup In The World Right Now - Green Queen Media - December 23rd, 2020
- The global cell isolation market size is projected to reach USD 15.0 billion by 2025 from USD 6.9billion in 2020, at a CAGR of 16.8% - GlobeNewswire - December 23rd, 2020
- How is the COVID-19 mRNA vaccine delivered to cells? - Massive Science - December 23rd, 2020
- US gets more help in raging battle against COVID-19 as FDA authorizes Moderna vaccine, the second allowed for emergency use - USA TODAY - December 20th, 2020
- NurOwn May Be Given to Early ALS Patients in US Who Finished Phase... - ALS News Today - December 20th, 2020
- A new psychedelic drug gives psychiatric benefits without causing hallucinations - Massive Science - December 20th, 2020
- ONK Therapeutics Announces Three Exclusive Option License Agreements, Which Extend and Strengthen its Dual-Targeted NK Cell Therapy Pipeline (1) -... - December 18th, 2020
- John Connolly has a new mission to tack on to his role at the Parker Institute: interim chief of a buzzy biotech backed by a pair of billionaires -... - December 18th, 2020
- Cell Replacement Therapy A Promising Treatment for Age-Related Macular Degeneration - Technology Networks - December 17th, 2020
- CRISPR Therapeutics Receives Grant to Advance In Vivo CRISPR/Cas9 Gene Editing Therapies for HIV - GlobeNewswire - December 17th, 2020
- ONK Therapeutics Announces Three Exclusive Option License Agreements, Which Extend and Strengthen its Dual-Targeted NK Cell Therapy Pipeline -... - December 17th, 2020
- The 10 Best Herbs for Liver Health: Benefits and Precautions - Healthline - December 17th, 2020
- Dr. Manjiri Bakre of OncoStem Diagnostics Recognised as One Among the Top 25 Voices in Precision Medicine Asia - Outlook India - December 17th, 2020
- Vascular therapies for mental health disorders - Open Access Government - December 17th, 2020
- Preliminary Results from NexImmune's Phase 1/2 Trial of NEXI-001 in AML Presented at 62nd ASH Annual Meeting and Exposition | DNA RNA and Cells | News... - December 13th, 2020
- City of Hope Doctors Present Innovative Therapies to Better Treat Blood Cancers at American Society of Hematology Virtual Conference - Business Wire - December 11th, 2020
- Translational Regenerative Medicine Market Top Companies Analysis To growing at CAGR of 12.13% by 20 - PharmiWeb.com - December 11th, 2020
- 3D Cell Culture Market by Scaffold Format, Products, Application Areas, Purpose, and Key Geographical Regions : Industry Trends and Global Forecasts,... - December 11th, 2020
- Could Gene Therapy Be Used To Mimic the Positive Effects of Exercise? - Technology Networks - December 11th, 2020
- The Technology Behind Bone Marrow Cellular Processing: The PXP System - Marketscreener.com - December 11th, 2020
- NASA-partnered Pluristem crashes to Earth as it axes leading therapy - FierceBiotech - December 11th, 2020
- Test-Tube-Treat: The Future Of Lab-Grown Meat - Impact Magazine - Impact Magazine - December 11th, 2020
- BeyondSpring Announces New Positive PROTECTIVE-2 Phase 3 Registrational Trial Results at the 2020 San Antonio Breast Cancer Symposium - BioSpace - December 11th, 2020
- Dr. Kansagra: Quadruplet Therapy for Newly Diagnosed Multiple Myeloma and Combination CAR T-Cell Opportunities - DocWire News - December 11th, 2020
- #ASH20: Orca's team showcases their first cut of the data on promising cell purification work for HSCT - Endpoints News - December 7th, 2020
- Negrin Shines Light on the Orca-T Story in GVHD - OncLive - December 7th, 2020
- Genetic engineering transformed stem cells into working mini-livers that extended the life of mice with liver disease - CT Post - December 7th, 2020
- Cord blood banks sell parents on promising stem cell research, but with no guarantees - The Arizona Republic - December 7th, 2020
- Bayer and Atara Biotherapeutics Enter Strategic Collaboration for Mesothelin-Targeted CAR T-cell Therapies for Solid Tumors - Business Wire - December 7th, 2020
- CRISPR Therapeutics and Vertex Present New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001 at American Society of Hematology Annual... - December 7th, 2020
- Allogene Therapeutics Presents Preclinical Data on ALLO-316 in Acute Myeloid Leukemia at the 62nd Meeting of the American Society of Hematology -... - December 7th, 2020
- Equillium Presents Translational Data Demonstrating Impact of Itolizumab on Effector T Cell Function at the 2020 American Society of Hematology Annual... - December 7th, 2020
- Clinical Trials Offer Opportunities to Change Practice to Improve Prevention and Treatment of Blood Disorders - PRNewswire - December 7th, 2020
- Circulating Tumor Cells and Cancer Stem Cells Market Size, Analysis, Regional Outlook, Competitive Strategies and Forecasts to 2027 - Cheshire Media - December 7th, 2020
- Sutro Biopharma Presents Data from Ongoing Phase 1 Dose-Escalation Study for STRO-001 for the Treatment of B-cell Non-Hodgkin Lymphoma at the 62nd... - December 7th, 2020
- Fate Therapeutics Reports Positive Interim Data from its Phase 1 Study of FT516 in Combination with Rituximab for B-cell Lymphoma - GlobeNewswire - December 7th, 2020
- #ASH20 UPDATED: Loxo and Eli Lilly show off PhI/II data for their BTK inhibitor in two blood cancers - Endpoints News - December 7th, 2020
- A 73-Year-Old-Woman Who Should Have Gotten Alzheimer's, Didn'tRevitalizing a Search for the Cure - Newsweek - December 7th, 2020
- Mini kidneys bioprinted in the lab - Lab + Life Scientist - December 1st, 2020
- Cryopreservation Equipment in Stem Cells Market 2020 Growth By Manufacturers, Type And Application, Forecast To 2026 : Thermo Fisher Scientific,... - December 1st, 2020
- Researchers make 'exciting first step' to better understanding development and treatment of autism - BioPharma-Reporter.com - December 1st, 2020
- Histogen Announces Preliminary Week 18 HST-001 Study Results for the Treatment of Androgenic Alopecia in Men - StreetInsider.com - December 1st, 2020
- US FDA Approves Naxitamab for the Treatment of Neuroblastoma - OncoZine - November 28th, 2020